Table of Contents
Overview
New York, NY – June 18, 2025 – Global Digital Breast Tomosynthesis Market Nsize is expected to be worth around US$ 10.2 Billion by 2034 from US$ 2.9 Billion in 2024, growing at a CAGR of 13.4% during the forecast period from 2025 to 2034. In 2024, North America led the market, achieving over 54.6% share with a revenue of US$ 1.5 Billion.
Digital Breast Tomosynthesis (DBT), also known as 3D mammography, is transforming breast cancer screening by providing clearer, more accurate imaging than traditional 2D mammography. This advanced imaging technique captures multiple X-ray images of the breast from different angles, creating a layered 3D reconstruction that enhances lesion visibility and reduces false positives.
The increasing global prevalence of breast cancer, which remains the most common cancer among women, has driven the adoption of DBT systems across hospitals, diagnostic centers, and specialty clinics. According to the World Health Organization (WHO), in 2022, over 2.3 million women were diagnosed with breast cancer worldwide. Early detection through advanced technologies such as DBT significantly improves survival rates and reduces treatment costs.
Government initiatives supporting breast cancer screening programs, especially in North America and Europe, are further accelerating DBT adoption. Additionally, technological advancements in detector sensitivity, image reconstruction software, and AI-based diagnostics are improving screening efficiency and clinical outcomes.
North America currently dominates the DBT market due to high screening awareness and established reimbursement frameworks. However, Asia-Pacific is projected to witness robust growth owing to rising healthcare infrastructure investments and growing awareness campaigns. As healthcare providers prioritize precision diagnostics, the digital breast tomosynthesis market is expected to expand steadily in the coming years, contributing to better patient outcomes and earlier cancer intervention.
Key Takeaways
- Market Size Overview: The global digital breast tomosynthesis (DBT) market is projected to reach approximately USD 10.2 billion by 2034, rising from an estimated USD 2.9 billion in 2024.
- Growth Rate: The market is anticipated to grow at a compound annual growth rate (CAGR) of 13.4% during the forecast period spanning 2025 to 2034.
- Product Type Insights: As of 2024, Standalone 3D tomosynthesis systems represent the leading product type in the market, accounting for nearly 76.8% of the total market share. This dominance is attributed to their widespread clinical adoption and superior diagnostic capabilities.
- End User Analysis: The hospital segment constitutes the largest end user category, holding approximately 46.7% of the global market share in 2024. Hospitals continue to be the primary facilities for advanced breast imaging and early cancer detection procedures.
- Regional Outlook: In 2024, North America emerged as the leading regional market, capturing more than 54.6% of the global share. The region’s market value stood at USD 1.5 billion, supported by robust healthcare infrastructure, established screening programs, and favorable reimbursement policies.
Segmentation Analysis
- Product Type Analysis: The Digital Breast Tomosynthesis (DBT) market is segmented into Standalone 3D Systems and 2D/3D Combination Systems. In 2024, Standalone 3D Systems accounted for 76.8% of the market share due to their superior imaging accuracy, particularly beneficial for dense breast tissue. However, the 2D/3D Combination Systems segment is expected to grow rapidly, as it offers dual-mode imaging flexibility, enhances workflow efficiency, and reduces examination time, making it an increasingly preferred option in modern diagnostic environments.
- End User Analysis: The DBT market by end-user includes Hospitals, Diagnostic Centers, and Others. As of 2024, Hospitals lead with 46.7% market share, driven by their role in comprehensive breast cancer care and their adoption of advanced diagnostic technologies. Diagnostic Centers follow as the second-largest segment, offering specialized, accessible imaging services. The Others category, comprising academic and research institutions, supports innovation through clinical trials and development. Together, these segments contribute significantly to advancing breast cancer screening and diagnosis worldwide.
Market Segments
By Product Type
- 2D/3D Combination Systems
- Standalone 3D Systems
By End Use
- Hospital
- Diagnostics Centers
- Others
Regional Analysis
In 2024, North America dominated the global digital breast tomosynthesis (DBT) market, holding over 54.6% market share with a valuation of USD 1.5 billion. This leadership is driven by the high prevalence of breast cancer, as highlighted by the CDC, and the increasing demand for early, accurate diagnostic technologies.
Government-endorsed screening initiatives, such as those by the U.S. Preventive Services Task Force and Medicare reimbursement support, have accelerated DBT adoption. Additionally, robust healthcare infrastructure, growing awareness, and the presence of leading imaging device manufacturers further strengthen the region’s market position.
Emerging Trends
- Widespread Adoption of DBT Units: It has been observed that the vast majority of certified mammography facilities in the United States now employ digital breast tomosynthesis. As of March 1, 2025, 8,266 out of 8,963 certified facilities were equipped with DBT units, reflecting an adoption rate of approximately 92.2 %.
- Integration of Artificial Intelligence: Growth in AI applications for DBT has been significant. Multi modal AI systems have been demonstrated to reduce patient recall rates by up to 31.7 % and decrease radiologist workload by 43.8 % while maintaining 100 % sensitivity in breast cancer screening.
- Improved Cancer Detection Rates: Meta analyses have indicated an incremental cancer detection rate increase of 1.6 cases per 1,000 screening examinations when DBT is added to conventional digital mammography protocols, after a prior negative assessment.
- Regulatory Support and Quality Standards: Following the 2023 MQSA Final Rule effective September 10, 2024, facilities have been required to comply with updated quality standards including breast density notification thereby reinforcing the adoption of advanced imaging modalities such as DBT.
Use Cases
- Screening Women with Dense Breast Tissue: DBT has been routinely employed for women with dense breasts, leading to improved lesion visibility and an incremental detection of 1.6 cancers per 1,000 screens compared with 2D mammography alone.
- Diagnostic Work up of Abnormal Findings: In cases of clinical symptoms or irregular screening results, DBT has been utilized to enhance diagnostic accuracy, offering superior characterization of masses and architectural distortions compared to conventional mammography.
- Reducing False Positive Recalls: When digital breast tomosynthesis was combined with full‐field digital mammography, recall rates among women without cancer were reduced from 38.4 % to 25.5 %, representing a 33 % decrease in unnecessary callbacks.
- Workflow Optimization through AI Assistance: AI algorithms have been applied to DBT for tasks such as case prioritization and automated lesion detection, resulting in a 43.8 % reduction in radiologist reading time and supporting faster clinical workflows.
Conclusion
The global Digital Breast Tomosynthesis (DBT) market is poised for substantial growth, driven by increasing breast cancer prevalence, technological advancements, and strong regulatory support. With a projected CAGR of 13.4% through 2034, DBT adoption is accelerating, particularly in hospitals and diagnostic centers. North America remains the leading region, while Asia-Pacific shows emerging potential.
Innovations such as AI integration, enhanced detection accuracy, and improved workflow efficiency continue to strengthen DBT’s role in early cancer diagnosis. As screening programs expand and imaging standards evolve, DBT is expected to remain a critical tool in advancing global breast health outcomes.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
